NAMS NewAmsterdam Pharma Company NV

$NAMS I think you’re overlooking a rather important detail. NewAmsterdam was issued U.S. Patent No. 12,006,305 in June 2024, covering the amorphous hemicalcium form of obicetrapib intended for commercialization, with an expected expiration in July 2043. That’s considerably more than five years. The distinction between crystalline and amorphous formulations also matters. The real discussion should be about patent enforceability and generic challenges, not whether the company has secured solid-form patent protection. The science deserves a discussion grounded in the facts.

$NAMS Just hard not to think that the big dogs have the inside scoop on how this trial is going

$NAMS Institutional investors own approximately 89.89% of NewAmsterdam Pharma’s (NAMS) outstanding stock. Because the company was backed heavily by early-stage funds, ownership trackers frequently divide this footprint between traditional institutions (holding roughly 70.2%) and Venture Capital / Private Equity firms (holding roughly 29%). The exact ownership percentages for the top major shareholders are broken down below: Holder Exact % of Ownership Shares Held As Of Date Frazier Life Sciences Management, LP 15.80% 18,938,902 Sept 18, 2026 Capital Research and Management Company 11.70% 13,954,052 June 30, 2026 FMR LLC (Fidelity) 8.65% 10,339,663 June 30, 2026 RA Capital Management, L.P. 7.99% 9,550,191 June 30, 2026 Forbion Capital Partners B.V. 7.10% 8,490,353 June 30, 2026 Deerfield Management Company, L.P. 3.57% 4,264,789 June 30, 2026 Viking Global Investors LP 3.52% 4,203,567 June 30, 2026 Bain Capital Life Sciences Investors, LLC 3.18% 3,806,566 June 30, 2026

$NAMS they've spend over a billion already on such a niche drug,I want the drug for health and longevity, but I don't think they will be able to price this correctly.

$NAMS one of the most encouraging things about NAMS is how quiet this message board is

$NAMS Merck's anacertrapib had 13% MACE reduction at 6 years. obicetrapib is more potent with superior safety profile. If PREVAIL MACE is over 15%, share price over $60. that is the bet

$NAMS another low volume day with shorts trying their best to offload their mistakes with this incredibly thin float. Good luck.

$NAMS CEO bought 10,000 shares on the open market. Frazier Life Sciences bought 850,000 more shares. These boys have the inside scoop. Structural bull case remains intact.

$NAMS the CEO explicitly bought shares on the open market. On September 14, 2026, CEO Michael H. Davidson purchased 10,000 ordinary shares at $22.65 each, amounting to a total personal commitment of $226,500.

$NAMS yeah, this is ugly no sugar coating it. we haven't even got the expected announcement of the PREVAIL trial continuation, which was expected to have a moderate negative effect on price.

$NAMS Top Institutional and Major Shareholders • Frazier Life Sciences Management, L.P. (including Frazier Life Sciences Public Fund) • Capital World Investors • FMR LLC (Fidelity) • RA Capital Management, L.P. • Deerfield Management Company, L.P. • Viking Global Investors Lp • Bain Capital Life Sciences Investors, LLC • Maverick Capital Ltd • Duquesne Family Office LLC • Forbion Capital Partners B.V. • Fcpm Iii Services B.v.

$NAMS Murdered YTD just like CELC, MLYS, VERA. Meanwhile, trash like IBRX and SLS is flying.